Abstract
Background: Fluticasone propionate was introduced in 1993 in the UK as a potentially safer inhaled corticosteroid than those already in use. The efficacy and safety of fluticasone has been established at recommended doses of 200 µg/day, but not at the higher doses that are often used.
Methods: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.
Findings: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. In one case the growth rate and cortisol response returned to normal 9 months after the fluticasone dose was reduced to 500 µg/day.
Interpretation: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.
Methods: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.
Findings: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. In one case the growth rate and cortisol response returned to normal 9 months after the fluticasone dose was reduced to 500 µg/day.
Interpretation: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.
Original language | English |
---|---|
Pages (from-to) | 27-29 |
Number of pages | 3 |
Journal | Lancet |
Volume | 348 |
Issue number | 9019 |
DOIs | |
Publication status | Published - 06 Jul 1996 |
Fingerprint
Dive into the research topics of 'Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate'. Together they form a unique fingerprint.Impacts
-
Improved management of airway disorders in children
Heaney, L. (Participant), Cadden, I. (Participant), Shields, M. (Participant), Ennis, M. (Participant), Schock, B. (Participant), Brown, V. (Participant), Ryan, M. (Participant), Carson, D. (Participant) & Warke, T. (Participant)
Impact: Health Impact, Quality of Life Impact